Molecular and Cellular Biochemistry

, Volume 295, Issue 1, pp 113–120

Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells

  • Nambi Aiyar
  • Jyoti Disa
  • Zhaohui Ao
  • Haisong Ju
  • Sandhya Nerurkar
  • Robert N. Willette
  • Colin H. Macphee
  • Douglas G. Johns
  • Stephen A. Douglas
Article

DOI: 10.1007/s11010-006-9280-x

Cite this article as:
Aiyar, N., Disa, J., Ao, Z. et al. Mol Cell Biochem (2007) 295: 113. doi:10.1007/s11010-006-9280-x

Abstract

Lysophosphatidylcholine (LPC) is the major bioactive lipid component of oxidized LDL, thought to be responsible for many of the inflammatory effects of oxidized LDL described in both inflammatory and endothelial cells. Inflammation-induced transformation of vascular smooth muscle cells from a contractile phenotype to a proliferative/secretory phenotype is a hallmark of the vascular remodeling that is characteristic of atherogenesis; however, the role of LPC in this process has not been fully described. The present study tested the hypothesis that LPC is an inflammatory stimulus in coronary artery smooth muscle cells (CASMCs). In cultured human CASMCs, LPC stimulated time- and concentration-dependent release of arachidonic acid that was sensitive to phospholipase A2 and C inhibition. LPC stimulated the release of arachidonic acid metabolites leukotriene-B4 and 6-keto-prostaglandin F, within the same time course. LPC was also found to stimulate basic fibroblast growth factor release as well as stimulating the release of the cytokines GM-CSF, IL-6, and IL-8. Optimal stimulation of these signals was obtained via palmitic acid-substituted LPC species. Stimulation of arachidonic acid, inflammatory cytokines and growth factor release, implies that LPC might play a multifactorial role in the progression of atherosclerosis, by affecting inflammatory processes.

Keywords

Human CASMCsLPCsignal transduction

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Nambi Aiyar
    • 1
  • Jyoti Disa
    • 1
  • Zhaohui Ao
    • 1
  • Haisong Ju
    • 3
  • Sandhya Nerurkar
    • 2
  • Robert N. Willette
    • 2
  • Colin H. Macphee
    • 1
  • Douglas G. Johns
    • 1
  • Stephen A. Douglas
    • 1
  1. 1.Department of Vascular Biology and ThrombosisCardiovascular and Urogenital Center of Excellence for Drug Discovery, GlaxoSmithKlineKing of PrussiaUSA
  2. 2.Department of Investigative BiologyCardiovascular and Urogenital Center of Excellence for Drug Discovery, GlaxoSmithKlineKing of PrussiaUSA
  3. 3.Department of Safety Assessment, Cardiovascular and Urogenital Center of Excellence for Drug DiscoveryGlaxoSmithKlineKing of PrussiaUSA